Description
2025 SUBCONTRACTING PLAN
Base award description: NEW AWARD FOR HUMAN INSULIN WITH NOVO NORDISK, INC. PERIOD OF PERFORMANCE IS 7/1/2020 - 6/30/2021 WITH FOUR ONE-YEAR OPTIONS.
First action · last action
2020-03-12 · 2025-01-10
Transactions
17
First transaction's obligation
$0
Base + all options value (sum of deltas)
$470,487,013
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 17 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-03-12+$0= $0
- Mod P000012020-12-04+$0= $0
- Mod P000022020-12-17+$0= $0
- Mod P000032021-05-17+$0= $0
- Mod P000042021-12-14+$0= $0
- Mod P000052021-12-20+$0= $0
- Mod P000062022-05-20+$0= $0
- Mod P000082022-12-02+$0= $0
- Mod P000072022-12-06+$0= $0
- Mod P000092023-04-20+$0= $0
- Mod P000102023-05-11+$0= $0
- Mod P000112023-12-05+$0= $0
- Mod P000122023-12-15+$0= $0
- Mod P000132024-04-09+$0= $0
- Mod P000142024-05-30+$0= $0
- Mod P000152024-12-03+$0= $0
- Mod P000162025-01-10+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-03-12 | +$0 | $0 | NEW AWARD FOR HUMAN INSULIN WITH NOVO NORDISK, INC. PERIOD OF PERFORMANCE IS 7/1/2020 - 6/30/2021 WITH FOUR ON… |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-12-04 | +$0 | $0 | 2021 PUBLIC LAW UPDATES. |
| Mod P00002· ADD SUBCONTRACTING PLAN | 2020-12-17 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE NOVO NORDISK'S 2021 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF… |
| Mod P00003· EXERCISE AN OPTION | 2021-05-17 | +$0 | $0 | EXERCISE OPTION YEAR 1 FOR HUMAN INSULIN WITH NOVO NORDISK. PERIOD OF PERFORMANCE IS 7/1/2021 - 6/30/2022. |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2021-12-14 | +$0 | $0 | 2022 PUBLIC LAW UPDATES. NATIONAL CONTRACT PRICING IS UNAFFECTED. |
| Mod P00005· ADD SUBCONTRACTING PLAN | 2021-12-20 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE NOVO NORDISK'S 2022 SUBCONTRACTING PLAN EFFECTIVE FOR THE PERIOD OF… |
| Mod P00006· EXERCISE AN OPTION | 2022-05-20 | +$0 | $0 | EXERCISE OPTION YEAR 2 ON CONTRACT 36E79720D0018 FOR HUMAN INSULIN WITH PRICE CHANGES. |
| Mod P00008· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-12-02 | +$0 | $0 | IMPLEMENT 2023 PUBLIC LAW UPDATES ON CONTRACT 36E79720D0018 FOR HUMAN INSULIN. |
| Mod P00007· ADD SUBCONTRACTING PLAN | 2022-12-06 | +$0 | $0 | IMPLEMENT 2023 SUBK PLAN ON CONTRACT 36E79720D0018 FOR HUMAN INSULIN. |
| Mod P00009· OTHER ADMINISTRATIVE ACTION | 2023-04-20 | +$0 | $0 | INCORPORATION OF DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE. |
| Mod P00010· EXERCISE AN OPTION | 2023-05-11 | +$0 | $0 | EXERCISE OPTION YEAR 3 FOR HUMAN INSULIN WITH PRICE CHANGES 7/1/2023 - 6/30/204. |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2023-12-05 | +$0 | $0 | 2024 PUBLIC LAW PRICING UPDATES |
| Mod P00012· ADD SUBCONTRACTING PLAN | 2023-12-15 | +$0 | $0 | INCORPORATE 2024 SUBCONTRACTING PLAN. |
| Mod P00013· OTHER ADMINISTRATIVE ACTION | 2024-04-09 | +$0 | $0 | IMPLEMENT COST RECOVERY FEE (CRF) CHANGES MOD. |
| Mod P00014· EXERCISE AN OPTION | 2024-05-30 | +$0 | $0 | EXERCISE OPTION YEAR 4 ON CONTRACT 36E79720D0018 FOR HUMAN INSULIN WITH PRICE CHANGES. |
| Mod P00015· OTHER ADMINISTRATIVE ACTION | 2024-12-03 | +$0 | $0 | 2025 PUBLIC LAW UPDATES |
| Mod P00016· ADD SUBCONTRACTING PLAN | 2025-01-10 | +$0 | $0 | 2025 SUBCONTRACTING PLAN |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI W72BJMJYBMN3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79725A0025 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36F79721D0044 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36E79720D0071 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2020 |
| 36F79719D0181 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2019 |
| VA797P15C0039 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2015 |
| VA24113F0882 | 241-NETWORK CONTRACT OFFICE 01 · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2013 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79720D0018_3600 · retrieved 2026-09-26.